このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Genscript Biotech マネジメント

マネジメント基準チェック /24

Genscript Biotech'sの CEO はWeihui Shaoで、 Jul2021年に任命され、の在任期間は 2.92年です。は、会社の株式の0.021%を直接所有しており、その価値はHK$ 4.19M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と7.2年です。

主要情報

Weihui Shao

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.9yrs
CEOの所有権	0.02%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	7.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Weihui Shao (44 yo)

2.9yrs

在職期間

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.6m
Weihui Shao	CEO & COO	2.9yrs	データなし	0.021% $ 4.1m
Ye Wang	Co-Founder	22.4yrs	US$615.00k	0.037% $ 7.1m
Shiniu Wei	Chief Financial Officer	3.5yrs	データなし	データなし
Fangliang Zhang	co-founder & Executive Director	1.5yrs	US$271.00k	データなし
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 11.3m
Wai Ling Wong	Company Secretary	8.8yrs	データなし	データなし

3.5yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 1548の経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.6m
Ye Wang	Co-Founder	9.1yrs	US$615.00k	0.037% $ 7.1m
Fangliang Zhang	co-founder & Executive Director	2.1yrs	US$271.00k	データなし
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 11.3m
George Church	Member of Advisory Board	4.8yrs	データなし	データなし
Yuexin Pan	Non-Executive Director	8.8yrs	US$64.00k	0.0027% $ 517.1k
Hong Xin Guo	Independent Non-Executive Director	8.8yrs	US$95.00k	0.0029% $ 565.9k
Zumian Dai	Independent Non-Executive Director	8.8yrs	US$105.00k	データなし
Xuehai Wang	Independent Non-Executive Director	3.6yrs	US$120.00k	データなし
Luquan Wang	Non-Executive Director	9.1yrs	データなし	0.030% $ 5.9m
Jiuan Pan	Independent Non-Executive Director	5.6yrs	US$124.00k	データなし
Jiafen Wang	Non-Executive Director	5.6yrs	US$51.00k	0.00019% $ 37.1k

7.2yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: 1548の取締役会は経験豊富であると考えられます ( 7.2年の平均在任期間)。

Genscript Biotech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Executive Chairman recently sold HK$610k worth of stock

Recent updates

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24